# Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

> **NCT01194245** · PHASE2 · COMPLETED · sponsor: **Halozyme Therapeutics** · enrollment: 135 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin lispro
- **DRUG:** recombinant human hyaluronidase PH20
- **DRUG:** Insulin aspart
- **DRUG:** Insulin glulisine
- **DRUG:** Insulin glargine

## Key facts

- **NCT ID:** NCT01194245
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194245, "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01194245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*